Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Douglas R Adkins, M.D.
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
- University of Mississippi Medical Center
Jackson, Mississippi, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States
- Sanford Cancer Center Oncology Clinic and Pharmacy
Sioux Falls, South Dakota, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Feb 2015
- Primary completion
- 15 May 2026
- Completion
- 15 May 2026
- Last update posted
- 5 May 2026
- Registered enrollment
- 74
- Registry id
- NCT02270814
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.